World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
91
Citations
48356
World Ranking
11527
National Ranking
430

Overview

Roberto Labianca is affiliated with the Mario Negri Institute for Pharmacological Research in Italy. Their research primarily centers on medical topics with a strong focus on oncology, particularly colorectal cancer treatments and studies.

The primary areas of study for Roberto Labianca include:

  • Medicine
  • Oncology
  • Pulmonary and Respiratory Medicine
  • Pathology and Forensic Medicine
  • Surgery
  • Cancer Research

Within these fields, notable topics of work cover:

  • Colorectal Cancer Treatments and Studies
  • Colorectal Cancer Surgical Treatments
  • Gastric Cancer Management and Outcomes
  • Genetic factors in colorectal cancer
  • Venous Thromboembolism Diagnosis and Management
  • Colorectal and Anal Carcinomas
  • Cancer Genomics and Diagnostics

Roberto Labianca has contributed extensively to several scientific journals. Frequent publication venues include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • European Journal of Cancer
  • JAMA Oncology
  • Cancers

Their recent papers reflect a focus on clinical oncology and treatment protocols with works such as:

  • Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2020, Annals of Oncology)
  • Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials (2020, The Lancet Oncology)
  • Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer (2021, Journal of Clinical Oncology)
  • Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial (2022, The Lancet Oncology)
  • Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials (2022, Journal of Clinical Oncology)

Collaboration appears significant in their work, with frequent co-authors including:

  • Sara Lonardi
  • Timothy Iveson
  • Julien Taïeb
  • Alberto Sobrero
  • Takayuki Yoshino

Best Publications

  • ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

    E. Van Cutsem;A. Cervantes;R. Adam;A. Sobrero

  • ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

    H J Schmoll;E Van Cutsem;A Stein;V Valentini

  • Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer

    Daniel J. Sargent;Silvia Marsoni;Genevieve Monges;Stephen N. Thibodeau

  • Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    R. Labianca;B. Nordlinger;G. D. Beretta;S. Mosconi

  • Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

    Sharlene Gill;Charles L. Loprinzi;Daniel J. Sargent;Stephan D. Thomé

  • Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer

    Philippe Rougier;Eric Van Cutsem;Emilio Bajetta;Norbert Niederle

  • Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial

    Christophe Louvet;R. Labianca;P. Hammel;G. Lledo

  • A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.

    Daniel J. Sargent;Richard M. Goldberg;Stacy D. Jacobson;John S. Macdonald

  • Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

    Arnaud D. Roth;Sabine Tejpar;Mauro Delorenzi;Pu Yan

  • Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

    Axel Grothey;Alberto F. Sobrero;Anthony F. Shields;Takayuki Yoshino

  • Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials

    Daniel J. Sargent;Harry S. Wieand;Daniel G. Haller;Richard Gray

  • Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study

    Giancarlo Agnelli;Gualberto Gussoni;Carlo Bianchini;Melina Verso

  • Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials

    Daniel Sargent;Alberto Sobrero;Axel Grothey;Michael J. O'Connell

  • Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized Trials

    Emmanuel Mitry;Anthony L.A. Fields;Harry Bleiberg;Roberto Labianca

  • Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

    R. Gralla;M. Lichinitser;S. Van der Vegt;H. Sleeboom

  • Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies

    Florence Huguet;Thierry André;Pascal Hammel;Pascal Artru

  • DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy

    Frank A. Sinicrope;Nathan R. Foster;Stephen N. Thibodeau;Silvia Marsoni

  • Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.

    Eric Van Cutsem;Roberto Labianca;György Bodoky;Carlo Barone

  • Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

    Volker Heinemann;Stefan Boeck;Axel Hinke;Roberto Labianca

  • Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

    Marina Chiara Garassino;Olga Martelli;Massimo Broggini;Gabriella Farina

Frequent Co-Authors

Sandro Barni
Sandro Barni Mario Negri Institute for Pharmacological Research
Stefano Cascinu
Stefano Cascinu Vita-Salute San Raffaele University
Valter Torri
Valter Torri Mario Negri Institute for Pharmacological Research
Mario Mandalà
Mario Mandalà European Institute of Oncology
Sara Lonardi
Sara Lonardi Istituto Oncologico Veneto
Axel Grothey
Axel Grothey University of Tennessee at Knoxville
Thierry André
Thierry André Université Paris Cité
Armando Santoro
Armando Santoro Humanitas University
David Cunningham
David Cunningham Royal Marsden NHS Foundation Trust

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in medicine doesn’t always begin with a traditional medical degree. There are many flexible, online alternatives that open doors into healthcare. For those eager to join the workforce quickly, accelerated lpn programs offer a faster route to becoming a Licensed Practical Nurse, combining convenience with solid job prospects.

Mental health professions are also in high demand. The shortest pmhnp program options allow registered nurses to advance their qualifications in psychiatric mental health, often in less time than traditional tracks.

Not all critical healthcare roles are clinical. Many students are turning to online healthcare administration programs to build careers in management, policy, and healthcare operations. Those seeking advanced roles can pursue affordable online mha programs, which can be completed entirely online and prepare graduates for leadership positions.

These diverse online degree pathways ensure you can find a study option that matches your timeline, budget, and career goals within the vast field of healthcare.

Best Scientists Citing Roberto Labianca

Trending Scientists

Recently Published Articles